Compare Veritone Inc (VERI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Veritone Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Veritone Inc trades at $0.58 (market cap $59.46M), while Vertex Pharmaceuticals Incorporated trades at $508.34 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2145.1× Veritone Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Veritone Inc for 12 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| VERI | VRTX | |
|---|---|---|
Market Cap | $59.46M | $127.55B |
Volume | 15,523,164 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $8.39 | $557.96 |
52-Week Low | $0.59 | $407.37 |
Typical Hold Time | 12 Days | 120 Days |
Enterprise Value | $94.86M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Veritone (VERI) trades at $0.61, down 11.76% in the last 24 hours, reflecting bearish technical signals. The company reported a net loss of $111.73 million in 2025, with negative profit margins and cash flow challenges, though revenue remains near $92 million. Recent news includes a $15 million equity offering and partnerships, but legal investigations and persistent losses weigh on sentiment.
The outlook is highly speculative, with a consensus price target of $3.75 suggesting significant upside if the company achieves profitability. However, high execution risk, cash burn, and legal overhangs present substantial downside, making the stock suitable only for risk-tolerant investors betting on a turnaround.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
